DBV Technologies to Participate in an Upcoming Investor Conference

Rhea-AI Summary

DBV Technologies, a clinical-stage biopharmaceutical company, announced participation in the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021. CEO Daniel Tassé will engage in a fireside chat at 8am ET. A live webcast will be available on the company’s website, with a replay following the event. DBV Technologies is focused on developing Viaskin, a proprietary platform aimed at food allergy treatment through epicutaneous immunotherapy. The company's shares are traded on Euronext and Nasdaq under symbols DBV and DBVT, respectively.

Montrouge, France, November 24, 2021

DBV Technologies to Participate in an Upcoming Investor Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the 4th Annual Evercore ISI HealthCONx Conference. Daniel Tassé, Chief Executive Officer, will participate in a fireside chat on Wednesday, December 1^st at 8am ET.

A live webcast of the fireside chat will be available on the Investors & Media section
of the Company’s website: https://www.dbv-technologies.com/investor-relations.

A replay will also be available on DBV Technologies’ website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com 

Attachment

• version PDF

FAQ

When will DBV Technologies participate in the Evercore ISI HealthCONx Conference?

DBV Technologies will participate in the Evercore ISI HealthCONx Conference on December 1, 2021.

Who will represent DBV Technologies at the conference?

CEO Daniel Tassé will represent DBV Technologies in a fireside chat at the conference.

What time is the DBV Technologies fireside chat?

The fireside chat will take place at 8am ET.

Where can I watch the DBV Technologies fireside chat?

The fireside chat will be available via a live webcast on the company's website.

What is the focus of DBV Technologies' research?

DBV Technologies is focused on developing Viaskin, an immunotherapy platform for treating food allergies.

What are the stock symbols for DBV Technologies?

The stock symbols for DBV Technologies are DBV on Euronext and DBVT on Nasdaq.